Highlights from the 51st Annual Conference of the European Society for Blood and Marrow Transplantation: Recognizing Award Recipients (O001-O007)

1

Ghosal hematodiaphyseal dysplasia (GHD) is a rare disorder characterized by severe anemia and painful cortical hypertrophy of long bones.
2

NSAIDs have been shown to be an effective first-line treatment for GHD, providing significant hemoglobin and platelet responses without major adverse effects.
3

Patients treated with NSAIDs achieved hemoglobin responses within a median of 3 months and platelet responses within 2 months.
4

Bone marrow biopsies in GHD patients revealed severe hypoplasia and interstitial edema, complicating diagnosis and treatment.
5

Screening for TBXAS1 mutations should be standard in inherited bone marrow failure syndromes, especially before hematopoietic stem cell transplantation.

1